61 completed, 10 unknown, 3 recruiting, 3 terminated. 39 Phase 3, 16 Phase 4, 11 Phase 2, 3 Phase 1, 2 Not applicable.
Follow Mumps: new trials by email Literature Review of Mumps trials Research Report on Mumps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine - Measles, Mumps | Phase 3 | Not yet recruiting | GlaxoSmithKline | 1860 | 2026-08-11 | 2026-08-03 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age MMRVNS, MMRV - Measles, Measles-Mumps-Rubella+Chickenpox Vaccine | Phase 3 | Recruiting | GlaxoSmithKline | 1209 | 2026-05-11 | 2026-07-08 |
| the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines Polio, Measles | Not yet recruiting | China National Biotec Group Company Limited | 600 | 2026-01-30 | 2026-01-14 | |
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 | |
| Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients Commercial measles, mumps, and rubella (MMR) vaccine - Heart Transplant Infection Prevention | Phase 4 | Recruiting | Children's Mercy Hospital Kansas City | 60 | 2025-09-11 | 2026-09-24 |
| A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults CVM150, CVM26, Placebo - Mumps | Phase 1 | Active not recruiting | CyanVac LLC | 60 | 2025-05-14 | 2025-12-11 |
| Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months SIBP MMR Vaccine, GSK MMR Vaccine (PRIORIX), Yellow Fever Vaccine (Stamaril) - Measles-Mumps-Rubella | Phase 3 | Completed | Shanghai Institute Of Biological Products | 1200 | 2024-06-28 | 2026-01-08 |
| Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine - Japanese Encephalitis, Measles | Phase 4 | Completed | Liaoning Chengda Biotechnology CO., LTD | 408 | 2024-03-02 | 2025-08-28 |
| Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination MMR booster vaccination (as M-M-R-VaxPro) - Mumps, Measles | Phase 3 | Unknown | University of Zurich | 200 | 2023-12-01 | 2024-01-08 |
| The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students Mumps vaccine, Live (MV), Influenza Vaccine, inactivated, quadrivlent(QIV) - Mumps, Influenza | Phase 4 | Unknown | Sinovac Biotech Co., Ltd | 400 | 2023-11-04 | 2024-01-17 |
| Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine, Inactivated SARS-CoV-2 vaccine coadministered with MMR, Inactivated SARS-CoV-2 vaccine administered alone - SARS-CoV-2 Infection, Varicella | Phase 4 | Unknown | Shanghai Municipal Center for Disease Control and Prevention | 540 | 2023-08-01 | 2023-07-19 |
| A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine - Measles; Mumps; Rubella; Chickenpox, Measles | Phase 2 | Completed | GlaxoSmithKline | 801 | 2022-12-14 | 2025-06-22 |
| The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine HPV+MMR（0d），HPV（6m）, HPV（0d），HPV（6m），MMR（7m）, MMR（0d），HPV（1m），HPV（7m） - Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18 | Phase 4 | Unknown | Zhejiang Provincial Center for Disease Control and Prevention | 300 | 2021-08-25 | 2022-03-29 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine Mumps vaccine, measles, mumps and rubella combined vaccine, live - Mumps | Phase 4 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 920 | 2020-11-18 | 2021-08-18 |
| Phase II/III of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Healthy Children Aged 5-11 Attenuated Mumps vaccine (KMB-17) in phase II and III, Placebo in phase II, Attenuated Mumps vaccine (KMB-17) in phase III - Epidemic Parotitis, Mumps | Phase 2 / Phase 3 | Unknown | Institute of Medical Biology, Chinese Academy of Medical Sciences | 11999 | 2020-10-12 | 2023-10-11 |
| Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old Safety group - Mumps | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 10000 | 2020-10-06 | 2021-12-06 | |
| Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants ≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old), ≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old), Measles and Mumps Combined Vaccine，Live(SIBP)( positive control) - Epidemic Parotitis,Mumps | Phase 2 | Unknown | Institute of Medical Biology, Chinese Academy of Medical Sciences | 1080 | 2017-05-20 | 2023-10-10 |
| Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Live attenuated SA 14-14-2 Japanese Encephalitis vaccine, Measles, mumps, rubella vaccine - Encephalitis, Japanese, Measles | Phase 4 | Completed | PATH | 628 | 2016-10-13 | 2020-10-14 |
| Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Measles, mumps and rubella Combined Vaccine, Live - Measles, Mumps | Phase 4 | Completed | Centers for Disease Control and Prevention, China | 873 | 2016-03-01 | 2017-05-19 |
| Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants investigational live attenuated mumps vaccine, control live attenuated mumps vaccine - Mumps | Phase 3 | Completed | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 1150 | 2016-01-01 | 2017-10-26 |
Showing 20 of 81. Sign in to see all of them.
Measles (71) · Rubella (69) · Chickenpox (44) · Haemophilus Infections (5) · Encephalitis, Japanese (4) · Hepatitis A (4) · Tetanus (4) · Meningitis, Meningococcal (3) · Poliomyelitis (3) · Whooping Cough (3) · Diphtheria (2) · Giardiasis (2) · Hepatitis B (2) · Meningitis (2)
Infections (81) · Mononegavirales Infections (81) · Mouth Diseases (81) · Paramyxoviridae Infections (81) · Parotid Diseases (81) · Parotitis (81) · RNA Virus Infections (81) · Rubulavirus Infections (81) · Salivary Gland Diseases (81) · Stomatognathic Diseases (81) · Virus Diseases (81) · Morbillivirus Infections (71) · Rubivirus Infections (69) · Togaviridae Infections (69) · DNA Virus Infections (46)
measles, mumps, rubella, varicella vaccine (22) · Measles-Mumps-Rubella Vaccine (16) · Chickenpox Vaccine (9) · Hepatitis A Vaccines (7) · Rubella Vaccine (5) · Heptavalent Pneumococcal Conjugate Vaccine (4) · 13-valent pneumococcal vaccine (3) · Meningococcal Vaccines (3) · Mumps Vaccine (3) · Vaccines (3) · Vaccines, Attenuated (3) · CRM197 (non-toxic variant of diphtheria toxin) (2) · DTPP vaccine (2) · Long-Term Synaptic Depression (2) · Priorix-Tetra vaccine (2)
GlaxoSmithKline (24) · Merck Sharp & Dohme LLC (18) · Sanofi Pasteur, a Sanofi Company (5) · Institute of Medical Biology, Chinese Academy of Medical Sciences (3) · Sinovac (Dalian) Vaccine Technology Co., Ltd. (3) · The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Assaf-Harofeh Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Centers for Disease Control and Prevention, China (1) · Children's Mercy Hospital Kansas City (1) · China National Biotec Group Company Limited (1) · CyanVac LLC (1) · Institut Pasteur du Cambodge (1) · Jiangsu Province Centers for Disease Control and Prevention (1)
United States (22) · China (14) · Germany (8) · Puerto Rico (7) · Italy (6) · Taiwan (6) · Finland (5) · France (4) · Brazil (3) · Estonia (3) · South Korea (2) · Spain (2) · Switzerland (2) · Argentina (1) · Austria (1)
Jingchen Ma (2) · Weijun Hu, Master (2) · Amanda Dempsey, MD, PhD, MPH (1) · Anne Fiquet, MD (1) · Beifang Yang, PhD (1) · Carl T. D'Angio, MD (1) · Claude Flamand, Ph.D. (1) · Eliane Matos Santos (1) · Eran Kozer (1) · Eva Netterlid (1) · Fenyang Tang (1)
PMID 16094218, PMID 16452343, PMID 16567978, PMID 16804432, PMID 17332177, PMID 17502347, PMID 19305145, PMID 19366435, PMID 20955461, PMID 22123890, PMID 22406278, PMID 22772170, PMID 24614759, PMID 25765966, PMID 26362659, PMID 27149048, PMID 27423382, PMID 28481690, PMID 29478347, PMID 29902133, PMID 30481110, PMID 31481612, PMID 36653029, PMID 37733724, PMID 41276263
2025 (2), 2014 (1)